Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | ADPT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.91 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.91 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.53 - 9.0799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.91 | USD |
Adaptive Biotechnologies Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 422.22M | 145.09M | - | 170.28M | -225.25M | -1.55 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adaptive Biotechnologies News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADPT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.85 | 3.12 | 2.53 | 2.92 | 2,651,203 | 0.06 | 2.11% |
| 1 Month | 3.14 | 3.52 | 2.53 | 2.94 | 1,942,035 | -0.23 | -7.32% |
| 3 Months | 4.36 | 4.49 | 2.53 | 3.46 | 1,597,025 | -1.45 | -33.26% |
| 6 Months | 4.24 | 5.49 | 2.53 | 3.99 | 1,570,249 | -1.33 | -31.37% |
| 1 Year | 7.97 | 9.0799 | 2.53 | 5.10 | 1,364,596 | -5.06 | -63.49% |
| 3 Years | 43.06 | 44.97 | 2.53 | 11.61 | 1,150,063 | -40.15 | -93.24% |
| 5 Years | 39.01 | 71.25 | 2.53 | 20.93 | 1,068,258 | -36.10 | -92.54% |
Adaptive Biotechnologies Description
| Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. |
